<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768608</url>
  </required_header>
  <id_info>
    <org_study_id>2020-CAR-00CH2</org_study_id>
    <nct_id>NCT04768608</nct_id>
  </id_info>
  <brief_title>PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer</brief_title>
  <official_title>Clinical Trial for the Safety and Efficacy of Non-viral PD1 Integrated Anti-PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castrate-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bioray Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial for the safety and efficacy of Non-viral programmed cell death protein-1(PD1)&#xD;
      integrated anti-prostate-specific-membrane-antigen(PSMA) chimeric antigen receptor T(CART)&#xD;
      cells in the treatment of Refractory Castrate-Resistant Prostate Cancer(CRPC)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Group A: 0.5×10^6 cells / kg; Group B: 1.0×10^6 cells / kg; Group C: 2.0×10^6 cells / kg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxicity graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>All adverse events (AEs) will be listed and summarized. Summaries of laboratory data will include, at a minimum, treatment-emergent laboratory abnormalities. Summaries of AEs and laboratory abnormalities will be based on the All Treated analysis set.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) response rate</measure>
    <time_frame>180 days</time_frame>
    <description>proportion of patients with ≥50% PSA decline from baseline at any time point after therapy and maintained for ≥4weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic response rate by RECIST 1.1 &amp; PCWG3</measure>
    <time_frame>180 days</time_frame>
    <description>Proportion of patients with a best response of either complete response or partial response, assessed using Prostate Cancer Working group3(PCWG3) response criteria &amp; Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of persistent CART cells detected by Quantitative Real-time Polymerase Chain Reaction or flow cytometry</measure>
    <time_frame>180 days</time_frame>
    <description>Number of persistent CART cells detected by Quantitative Real-time Polymerase Chain Reaction or flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Castrate-Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PD1-PSMA-CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo leukapheresis by receiving cyclophosphamide and fludarabine on days -6 to -4, and then receive PD1-PSMA-CART intravenous injection (IV) at split doses from day 0 on.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD1-PSMA-CART cells</intervention_name>
    <description>PD1-PSMA-CART cells will be given IV at split doses</description>
    <arm_group_label>PD1-PSMA-CART</arm_group_label>
    <other_name>Non-viral PD1 integrated anti-PSMA chimeric antigen receptor T cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fully understand and voluntarily sign informed consent.&#xD;
&#xD;
          -  Aged 18 to 75 years old.&#xD;
&#xD;
          -  Expected survival &gt; 6 months.&#xD;
&#xD;
          -  CRPC patients:Serum testosterone reached castration level (&lt;50ng/dl or&lt;1.7nmol/L) and:&#xD;
             prostate specific antigen (PSA) increased more than 50% at intervals of one week or&#xD;
             three consecutive times, with PSA&gt;2 ng/ml; or imaging scans revealed two or more new&#xD;
             lesions or enlargement of soft tissue lesions that met the criteria for evaluating&#xD;
             solid tumor response.&#xD;
&#xD;
          -  CRPC patients received abiraterone or chemotherapy for 3 months or more, and were&#xD;
             ineffective or progressive (PSA continued to rise for 3 months, or bone&#xD;
             scan/whole-body imaging showed local recurrence or new metastasis).&#xD;
&#xD;
          -  Immunohistochemical staining of repetitive biopsy tissues showed the expression of&#xD;
             PSMA in tumor cells was more than 50%.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score ≤2.&#xD;
&#xD;
          -  Virological examination was negative.&#xD;
&#xD;
          -  Hematological indexes: hemoglobin &gt; 100 g/L, platelet count &gt; 100×10^9/L, absolute&#xD;
             neutrophil count &gt; 1.5×10^9/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any CART therapy targeting any target.&#xD;
&#xD;
          -  Prior treatment with any PSMA targeting therapy.&#xD;
&#xD;
          -  Need steroid therapy, except physiological replacement therapy.&#xD;
&#xD;
          -  Prior treatment with any immunotherapy, including tumor vaccine therapy, radium-223,&#xD;
             checkpoint inhibitors and others.&#xD;
&#xD;
          -  Subjects with severe mental disorders.&#xD;
&#xD;
          -  Subjects with other malignant tumors.&#xD;
&#xD;
          -  Subjects with severe cardiovascular diseases: a, New York Heart Association (NYHA)&#xD;
             stage III or IV congestive heart failure; b, history of myocardial infarction or&#xD;
             coronary artery bypass grafting (CABG) within 6 months; c, clinical significance of&#xD;
             ventricular arrhythmia, or history of unexplained syncope, non-vasovagal or&#xD;
             dehydration; d, history of severe non-ischemic cardiomyopathy; e, the left ventricular&#xD;
             ejection fraction (left ventricular ejection fraction&lt; 55%) was decreased by&#xD;
             echocardiography or multiple gated acquisition scan (within 8 weeks before peripheral&#xD;
             blood mononuclear cell (PBMC) collection), and abnormal interventricular septal&#xD;
             thickness and atrioventricular size associated with myocardial amyloidosis.&#xD;
&#xD;
          -  Patients with ongoing or active infection.&#xD;
&#xD;
          -  Organ function: a, Alanine aminotransferase or Aspartate aminotransferase &gt;2.5*Upper&#xD;
             limit of normal (ULN); Creatine kinase&gt;1.5*ULN; Creatine kinase isoenzyme &gt;1.5*ULN;&#xD;
             Troponin T &gt;1.5*ULN; b, Total bilirubin &gt;1.5*ULN; c, Partial prothrombin time or&#xD;
             activated partial thromboplastin time or international standardized ratio &gt; 1.5*ULN&#xD;
             without anticoagulant treatment.&#xD;
&#xD;
          -  History of participation in other clinical studies within 3 months or treatment with&#xD;
             any gene therapy product.&#xD;
&#xD;
          -  Intolerant or allergic to cyclophosphamide or fludarabine.&#xD;
&#xD;
          -  Subjects not appropriate to participate in this clinical study judged by&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weijia Fang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weijia Fang, MD</last_name>
    <phone>13758211655</phone>
    <email>weijiafang@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weijia Fang, MD</last_name>
      <phone>13758211655</phone>
      <email>weijiafang@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Weijia fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Weijia Fang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Castrate-Resistant Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

